These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Author: Lukkarinen O, Kontturi M.
    Journal: Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121.
    Abstract:
    We treated 38 patients with newly diagnosed advanced prostatic cancer with monthly injections of a long acting depot preparation of a luteinizing hormone-releasing hormone superagonist (Zoladex depot). After 6 months' treatment 10% of the patients had complete objective regression, 77% had partial objective regression, 3% stable disease and 10% had objective progression. The LHRH analogue does not have the metabolic side effects of oestrogens. Depot luteinizing hormone-releasing hormone analogue may well become a preferred alternative for patients with advanced prostatic cancer.
    [Abstract] [Full Text] [Related] [New Search]